Middle-aged individuals may be in a perpetual state of H3N2 influenza 1

virus susceptibility 2

4	Sigrid Gouma ¹ , Kangchon Kim ² , Madison Weirick ¹ , Megan E. Gumina ¹ , Angela Branche ³ , David
5 6	J. Topham ⁺ , Emily T. Martin [°] , Arnold S. Monto [°] , Sarah Cobey ² , and Scott E. Hensley ¹
8 7 8	¹ Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
9	² Department of Ecology & Evolution, University of Chicago, Chicago, IL 60637, USA
10 11	³ Division of Infectious Diseases, University of Rochester Medical Center, Rochester, NY, 14642 USA
12 13 14	⁴ Department of Medicine and Department of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY, 14642 USA
15 16 17 18 19 20	⁵ Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
21 22	*corresponding author: 402 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104. Phone: (215) 573-3756. Email: hensley@pennmedicine.upenn.edu
23	
24	
25	
26	Keywords: hemagglutinin, neutralizing antibodies, immune imprinting
27	
28	

29 Most humans are infected with influenza viruses by 3-4 years of age (1) and have high 30 antibody titers against viral strains encountered early in life (2). Early childhood influenza 31 exposures can leave lifelong 'immunological imprints' that affect how an individual 32 responds to antigenically distinct viral strains later in life (3,4). H3N2 influenza viruses 33 began circulating in humans in 1968 and have evolved substantially over the past 51 years 34 (5). Therefore, an individual's birth year largely predicts which specific type of H3N2 virus 35 they first encountered in childhood. Here, we completed a large serological survey to 36 elucidate the specificity of antibodies against contemporary H3N2 viruses in differently 37 aged individuals who were likely primed with different H3N2 strains in childhood. We found 38 that most humans who were first infected in childhood with H3N2 viral strains from the 39 1960s and 1970s possess non-neutralizing antibodies against contemporary 3c2.A H3N2 40 viruses. Most importantly, we found that 3c2.A H3N2 virus infections boost non-41 neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them 42 in a perpetual state of 3c2.A H3N2 viral susceptibility.

43 An antigenically drifted descendant of the original 1968 H3N2 strain, designated as clade 3c2.A 44 H3N2 viruses, emerged during the 2014-2015 influenza season (6) and continues to circulate at 45 high levels across most parts of the world (7). 3c2.A H3N2 viruses are unique because they 46 possess a key glycosylation site that shields HA antigenic site B, which is a major target of 47 neutralizing antibodies (8). During the 2017-2018 season, 3c2.A H3N2 viruses caused a lot of 48 hospitalizations and deaths in the United States (9). Influenza activity is often first detected in 49 children within the community; however, during the severe 2017-2018 influenza season, influenza 50 activity in middle-aged and older adults peaked earlier than in children and young adults (9). It is 51 surprising that 3c2.A H3N2 viruses dominated the 2017-2018 season in the United States since 52 these viruses also dominated the 2014-2015 and 2016-2017 United States influenza seasons, 53 and therefore many people likely had immunity against these viruses. It is unknown if 3c2.A 54 viruses were able to circulate widely in 3c2.A H3N2-exposed populations during the 2017-2018

55 season by acquiring HA and NA substitutions that facilitate antibody escape. Further, it is 56 unknown why these viruses exhibited unusual age-related patterns of circulation during that 57 season and whether or not this was a consequence of different H3N2 exposure histories in 58 different aged individuals.

59 To determine if HA and/or NA substitutions in 3c2.A H3N2 viruses contributed to the atypical 60 2017-2018 influenza season in the United States, we completed a large serological survey using 61 samples collected from differently aged individuals in the summer months prior to the 2017-2018 62 influenza season. We tested sera from individuals with different birth years so that we would be 63 able to identify antibody signatures that were associated with distinct H3N2 childhood immune 64 imprinting. In total, we tested serum samples collected from 140 children (age 1-17) at the 65 Children's Hospital of Philadelphia and 212 adults (age 18-90) at the Hospital of the University of 66 Pennsylvania (Extended Data Table 1).

67 First, we used ELISA to measure antibody binding to recombinant HA proteins from a 3c2.A 68 virus from 2014 (herein referred to as 3c2.A) and from a 3c2.A virus from 2018 (herein referred 69 to as 3c2.A2). The HA of 3c2.A2 H3N2 viruses from 2018 possesses 3 amino acid substitutions 70 (T131K, R142K, and R261Q) relative to the HA of 3c2.A H3N2 viruses from 2014 (10). Most 71 individuals 4 years of age and older possessed 3c2.A and 3c2.A2 HA ELISA-reactive antibodies 72 (Fig. 1a and d). Only 38 of 352 serum samples had no detectable HA reactive antibodies. Thirty-73 five of the 38 donors with no detectable HA-reactive antibodies were under 4 years of age, and it 74 is likely that these individuals were not previously exposed to H3N2 virus. Importantly, we found 75 no major differences in mean serum antibody binding to 3c2.A HA compared to 3c2.A2 HA (Fig. 76 1g).

Our ELISAs are designed to detect all HA-binding antibodies, and these assays cannot distinguish between neutralizing and non-neutralizing antibodies. Therefore, we next completed neutralization assays using 3c2.A and 3c2.A2 viruses. These assays primarily measure neutralizing HA antibodies and do not efficiently detect non-neutralizing HA or most NA

81 antibodies. Contrary to what we found in ELISAs, most individuals did not possess high levels of neutralizing antibodies against either 3c2.A or 3c2.A2 viruses (Fig. 1b). Sera from children aged 82 83 3-10 years old possessed the highest levels of neutralizing antibodies against these viruses 84 (p<0.0007 when compared to all other age groups for both 3c2.A and 3c2.A2 titers, Extended 85 Data Table 2), whereas most middle-aged adults did not have detectable neutralizing antibody 86 titers. Among adults, neutralizing antibody titers were lowest in individuals ~50 years of age. This 87 is notable since 50 year olds were born in 1967, one year before H3N2 viruses began circulating 88 in humans. Neutralizing antibody titers against 3c2.A2 virus were lower compared to titers against 89 3c2.A virus in serum from some individuals, but only 37 individuals (11%) had a \geq 4-fold decrease 90 in neutralizing antibody titer to this virus (Fig. 1h and Extended Data Fig. 1). These data suggest 91 that 2017-2018 H3N2 viruses did not possess significant HA antigenic changes relative to 2014-92 2015 H3N2 viruses for most humans; however a large fraction of the adult population possessed 93 non-neutralizing antibodies that could bind to the HAs of these viruses but could not prevent virus 94 infection.

95 We next completed experiments to measure serum antibody binding to NA. Antibodies against 96 NA typically do not neutralize virus infection (11), so we completed Enzyme-Linked Lectin Assays 97 (ELLAs) that measure antibodies that block NA cleavage of sugars on fetuin proteins (12). Similar 98 to HA neutralizing antibody titers, NA-specific antibody titers were highest in younger individuals 99 and lowest in middle-aged adults (Fig. 1c). Consistent with a recent report (13), we found that 100 some individuals possessed antibodies that reacted to the NA of 3c2.A viruses more efficiently 101 compared to the NA of 3c2.A2 viruses (Fig. 2c, f and i). The NA of 3c2.A2 viruses possesses a 102 new glycosylation site at residue 245 (enabled by S245N+S247T substitutions relative to the NA 103 of 3c2.A NA) that alters antibody binding (13). Interestingly, antibodies that were able to 104 antigenically distinguish the 3c2.A and 3c2.A2 NAs were more prevalent in individuals younger 105 than 25 years of age (Fig. 1c, f and i).

106 It is unclear why many adults born ~1968 possessed low levels of 3c2.A and 3c2.A2 HA 107 neutralizing antibodies and NA antibodies prior to the 2017-2018 influenza season. It is possible, 108 although unlikely, that 3c2. A viruses did not infect this age group during the previous 2014-2015 109 and 2016-2017 influenza seasons. An alternative hypothesis is that individuals born ~1968 were 110 infected as much as other adults during the previous 3c2.A H3N2-dominated seasons but failed 111 to mount neutralizing antibody responses that could confer protection during the 2017-2018 112 season. To address this possibility, we measured HA and NA antibodies in 14 middle-aged adults 113 (years of birth ranging from 1963-1979) before and after laboratory-confirmed 3c2.A H3N2 114 influenza virus infection during the 2014-2015 season. These samples were collected as part of 115 the Household Influenza Vaccine Effectiveness (HIVE) study in Ann Arbor, Michigan (14). 116 Consistent with the hypothesis that 3c2.A H3N2 viruses elicit a non-neutralizing antibody 117 response in middle-aged adults, we found that HA ELISA antibody titers increased in the serum 118 of most individuals 4-8 months after infection (Fig. 2a), but neutralizing antibody titers remained 119 low in the same individuals (Fig. 2b). 3c2.A NA inhibitory antibodies increased in the serum of 120 most infected individuals and these antibodies reacted less well to the antigenically drifted 3c2.A2 121 NA from 2018 (Fig. 2c). We found similar results when we analyzed serum samples from a 122 separate smaller cohort of individuals (n=6) collected 28 days post-infection in Rochester, New 123 York during the 2016-2017 season (Extended Data Fig. 2).

124 The HAs of 1968 H3N2 viruses and contemporary 3c2.A H3N2 viruses are dissimilar and most 125 epitopes conserved between these HAs are non-neutralizing (Fig. 3a). We hypothesize that 126 individuals 'imprinted' with H3N2 viruses in childhood in the 1960s and 1970s produce mostly 127 non-neutralizing HA antibodies against 3c2.A viruses because most of the 3c2.A HA memory B 128 cells in these individuals are those that target non-neutralizing epitopes. We further hypothesize 129 that 3c2.A infections in younger individuals do not elicit the same non-neutralizing responses 130 since younger individuals have been primed with viruses more closely related to 3c2.A (Fig. 3a) 131 or they have not yet been primed with H3N2 at all. Since H3N2 viruses have evolved continuously

132 since 1968, individuals born more recently were likely 'imprinted' with an H3N2 strain that shares some neutralizing HA epitopes with 3c2.A viruses compared to individuals born closer to 1968. 133 134 To model this, we calculated the probability of being 'imprinted' with H3N2 for differently aged 135 individuals, taking into account the similarity of the HAs of the 'imprinting' H3N2 viral strain with 136 the HA of 3c2.A viruses (Fig. 3b). Similarity between the HA of the 'imprinting' H3N2 strain and 137 the HA of 3c2.A viruses was determined based on amino acid sequences (see Methods). We 138 compared our model predictions with 3c2.A H3N2 neutralizing antibody titers in differently aged 139 individuals (Fig. 3b). Most older individuals were not likely imprinted with H3N2 viruses, since 140 these viruses did not start circulating until 1968. Antibody titers against 3c2.A viruses in these 141 older individuals were at similar levels compared to young individuals. Conversely, most 142 individuals born after 1968 were likely imprinted with an H3N2 virus, and this imprinting probability 143 varies for each year of birth after 1977 since H1N1 viruses dominated some influenza seasons 144 after 1977. In our model, being imprinted with an H3N2 virus did not correlate with neutralizing 145 antibody titers to 3c2.A viruses (Extended Data Table 3). However, similarity between the HAs of 146 the imprinting H3N2 viral strain and the 3c2.A H3N2 viral strain had a positive effect on 147 neutralizing antibody titers (p<0.001, Extended Data Table 3). Younger individuals who were 148 imprinted with an H3N2 virus with an HA that is more similar to the HA of 3c2.A H3N2 virus were 149 more likely to possess neutralizing 3c2.A H3N2 antibodies compared to middle-aged adults who 150 were imprinted with an H3N2 virus that has an HA that is more distant compared to the HA of 151 3c2.A H3N2 viruses. Taken together, our imprinting model suggests that the specific type of H3N2 152 virus that an individual is exposed to early in life can affect the specificity of antibody responses 153 against contemporary 3c2.A H3N2 viruses.

We propose that middle-aged individuals may be continuously susceptible to 3c2.A H3N2 infection since we found that these viruses preferentially elicit non-neutralizing HA antibody responses in this age group. While non-neutralizing HA and NA antibodies can stop viral spread and help resolve infections, these antibodies do not typically prevent infections. Although

speculative, it is possible that the presence of high levels of non-neutralizing antibodies in middleaged adults has contributed to the continued persistence of 3c2.A viruses in the human population. Our findings might also relate to the unusual age distribution of H3N2 infections during the 2017-2018 season, in which H3N2 activity in middle-aged and older adults peaked earlier compared to children and young adults (9).

163 It is interesting that we detected significant NA antigenic change, but only minor HA antigenic 164 change in viral isolates from the severe 2017-2018 season. We speculate that individuals with 165 non-neutralizing HA antibody responses might rely on NA immunity, and it is possible that this 166 has led to immune pressure on NA and the emergence of viruses with antigenically relevant NA 167 substitutions. We found that NA substitutions in 3c2.A2 viruses from the 2017-2018 season 168 reduced antibody recognition in serum from all age groups but especially from individuals 25 years 169 old and younger. Further studies should be designed to tease out the protective role and interplay 170 of HA and NA antibodies during the 2017-2018 season.

171 Our findings might shed light on the relatively low effectiveness of 3c2.A H3N2-based vaccines 172 over the past 3 years (15–17). Low effectiveness of 3c2.A H3N2-based vaccines is partially due 173 to the inherent difficulties of preparing egg-based 3c2.A H3N2 antigens (18). 3c2.A H3N2 viruses 174 cannot grow in fertilized chicken eggs without first acquiring an amino acid substitution that 175 abrogates a key glycosylation site in HA antigenic site B, and this egg-adaptation can dramatically 176 alter antigenicity (8,19). Our study demonstrates that it is difficult to elicit neutralizing antibody 177 responses against 3c2.A H3N2 viruses in some individuals even after natural infection with these 178 viruses. Therefore, irrespective of issues related to 3c2.A H3N2-egg adaptations, it may be 179 inherently difficult to design 3c2.A H3N2 vaccine antigens that are able to elicit neutralizing 180 antibodies in humans that were exposed early in childhood with H3N2 viruses in the 1960s and 181 1970s.

Future studies should continue to evaluate the specificity of influenza virus antibodies in differently aged individuals. A better understanding of immunity within the population and within

individuals will likely lead to improved models that are better able to predict the evolutionary trajectories of different influenza virus strains. Large serological studies and basic immunological studies may ultimately shed light on why influenza vaccines elicit variable responses in individuals with different immune histories, while identifying barriers that need to be overcome in order to design better vaccines that are able to elicit protective responses in all age groups.

189 Materials and Methods

190 Human serum samples

191 Serum samples from 140 children (1 to 17 years old) were collected at the Children's Hospital of 192 Philadelphia (CHOP) between May-August of 2017. Serum samples were originally collected from 193 children for lead testing and leftover de-identified samples were then used for this study. Serum 194 samples from 212 adults (18-90 years old) were collected via the Penn BioBank between May-195 August of 2017. The Penn BioBank routinely collects serum samples from individuals visiting the 196 University of Pennsylvania Health care system. We did not include samples collected by the Penn 197 BioBank from donors who had a pregnancy reported during the last 9 months, who had a medical 198 history of cancer or organ transplantation, or who had a reported infectious disease within the 199 previous 28 days. We also tested serum collected before and after laboratory confirmed 3c2.A 200 H3N2 infections during the 2014-2015 and 2016-2017 influenza seasons. The 2014-2015 201 samples were collected from individuals participating in the Household Influenza Vaccine 202 Effectiveness (HIVE) study in Ann Arbor, Michigan (14). Serum samples from this study were 203 collected 0-3 months before and 4-8 months after laboratory-confirmed 3c2.A H3N2 infection. The 204 2016-2017 samples were collected from individuals infected in Rochester, NY. Samples from this 205 study were collected at time of laboratory confirmed 3c2.A H3N2 infection (referred to in this 206 manuscript as 'pre-infection') and 28 days later (post-infection samples). All studies involving 207 human samples were approved by the Institutional Review Boards of the University of Michigan, 208 University of Rochester, and the University of Pennsylvania.

209 Viruses and recombinant proteins

210 All viruses used in this study were generated by reverse-genetics. HA and NA genes from 211 A/Colorado/15/2014 (3c.2A) or A/Pennsylvania/49/2018 (3c.2A2) were cloned into the pHW2000 212 reverse genetics plasmid as described (20). Viruses were rescued using HA and NA genes from 213 A/Colorado/15/2014 or A/Pennsylvania/49/2018 H3N2 viruses and internal genes from A/Puerto 214 Rico/8/1934. For NA experiments. with we generated viruses H6 215 (A/turkey/Massachusetts/3740/1965) and N2 (from either A/Colorado/15/2014 or 216 A/Pennsylvania/49/2018). Viruses were rescued by transfecting reverse-genetics plasmids into 217 co-cultures of 293T and MDCK-SIAT1 cells. Transfection supernatants were harvested 3 days 218 after transfection and stored at -80°C. HA and NA genes were sequenced to confirm that 219 additional mutations did not arise during transfection. For the production of recombinant HA 220 proteins, 1x10⁸ 293F cells were transfected with 70 µg codon-optimized A/Colorado/15/2014 HA 221 plasmid in the presence of 10 µg NA plasmid using polyethylenimine transfection reagent. 222 Proteins were purified after 3 days and the amount of recombinant HA for both constructs was 223 normalized prior to use in ELISA.

224 Foci Reduction Neutralization Test (FRNT)

225 Prior to testing in FRNT, serum samples were treated with receptor-destroying enzyme (RDE, 226 Denka Seiken) for 2 hours at 37°C and the enzyme was then heat-inactivated at 55°C for 30 227 minutes. RDE-treated serum samples were serially diluted in twofold in MEM (Gibco). Virus was 228 diluted to a concentration of approximately 300 focus-forming units per well and then incubated 229 with serum samples for 1 hour at room temperature. Confluent monolayers of MDCK-SIAT1 cells 230 were washed twice with MEM and then 100 µL of virus-serum mixtures were added to each well 231 in a 96-well plate. Cells were incubated for 1 hour at 37°C in 5% CO₂ and then washed with MEM. 232 An overlay of 1.25% Avicel in MEM supplemented with 0.2% gentamicin and 1% 1M HEPES was 233 then added to the cells. After 18 hours incubation at 37°C in 5% CO₂, cells were fixed with 4%

234 paraformaldehyde for 1 hour at 4°C. Cells were then lysed with 0.5% Triton X-100 in PBS for 7 235 minutes followed by blocking with 5% milk in PBS for 1 hour at room temperature. Plates were 236 washed and then 50 µL of anti-NP monoclonal antibody IC5-1B7 (BEI) 1:5000 diluted in 5% milk 237 in PBS was added to each well. After incubation for 1 hour at room temperature, plates were 238 washed and 50 µL of anti-mouse peroxidase-conjugated secondary antibody (Fisher) 1:1000 239 diluted in 5% milk in PBS was added to each well. Plates were incubated for 1 hour at room 240 temperature, washed, and then TMB substrate (Kirkegaard & Perry Laboratories) was added for 241 visualization of the foci. Plates were imaged and foci were quantified using an ELISpot reader. 242 FRNT₉₀ titers are reported as the reciprocal of the highest dilution of sera that reduced the number 243 of foci by at least 90%, relative to control wells that had no serum added. An anti-244 A/Colorado/15/2014 polyclonal serum in-house control was included in each assay run. Serum 245 samples that did not reduce the number of foci by at least 90% reduction at a 1:20 serum dilution 246 were assigned an FRNT₉₀ titer of 10.

247 Enzyme-Linked Immunosorbent Assay (ELISA)

248 ELISA plates were coated overnight at 4°C with recombinant HA protein. The next day, ELISA 249 plates were blocked for 2 hours with PBS containing 3% BSA. Plates were washed 3 times with 250 PBS containing 0.1% Tween 20 (PBS-T) and 50 µL of diluted serum was added to each well. 251 After 2 hours of incubation, plates were washed 3 times with PBS-T and then 50 µL peroxidase-252 conjugated anti-human secondary antibody (Jackson ImmunoResearch) diluted in PBS 253 containing 3% BSA was added to each well. After an hour incubation, plates were washed 3 times 254 with PBS-T. SureBlue TMB substrate (KPL) was added to develop the plates, and 5 minutes later 255 250 mM hydrochloric acid was added to stop the reaction. Plates were read at an optical density 256 (OD) of 450 nm using the SpectraMax 190 microplate reader (Molecular Devices). Monoclonal 257 antibody 041-10047-1C04 was included on each plate as a control, and IgG concentrations were

calculated based on the titration curve of this antibody (21). After background subtraction, serum
 samples that had an IgG concentration below the limit of detection were assigned an IgG
 concentration of 0.5 μg/mL.

261 Enzyme-Linked Lectin Assay (ELLA)

262 ELLAs were completed to measure NA-specific antibody titers. Microtiter 96-well plates were 263 coated with fetuin diluted in coating solution (KPL) and incubated overnight at 4°C. Heat-264 inactivated serum samples were serially diluted twofold in PBS containing 1% BSA and 0.1% 265 Tween 20. Coated plates were washed with PBS-T and 50 µL of diluted serum was added to each 266 well. Virus was diluted to the appropriate concentration and 50 μ L of virus was added to each 267 well. Plates were incubated overnight at 37°C. The next day, plates were washed with PBS-T and 268 peanut agglutinin conjugated to HRP (PNA-HRP; Sigma) diluted in PBS containing 1% BSA was 269 added to each well. Plates were incubated for 1 hour at room temperature and then washed with 270 PBS-T. SureBlue TMB substrate (KPL) was added to each well to develop the plates and after 5 271 minutes the developing process was stopped with 250 mM hydrochloric acid. Plates were read at 272 an optical density (OD) of 450 nm using the SpectraMax 190 microplate reader (Molecular 273 Devices). After background subtraction, ELLA₅₀ titers were reported as the reciprocal of the 274 highest dilution of sera that reduced the OD value by at least 50%, relative to control wells that 275 had no serum added. Serum samples that did not show at least 50% reduction in the OD value 276 at a 1:20 serum dilution were assigned an ELLA₅₀ titer of 10.

277 Modeling

278 Imprinting probability

To calculate the probability of being imprinted with H3N2, we followed the approach of Gostic *et al.* 2016 (4) and estimated the risk of primary H3N2 infection for each birth cohort using surveillance data on the relative intensity of the influenza season, the percentage of influenza A

isolates of each subtype that season, and typical attack rates in young children. We defined an influenza season *t* as from week 40 of year *t*-1 to week 39 of year *t*. The intensity of influenza A in season *t*, I_t , was calculated as

285

$$I_t = \operatorname{ILI}_t q_t^A$$
,

where ILI_t is the mean fraction of all people with influenza-like illness (ILI) in season t, and q_t^A is 286 287 the proportion of respiratory specimens testing positive for influenza A out of all respiratory 288 specimens tested in season t. For the 1997-98 to the 2016-17 seasons, data on ILI and respiratory 289 specimens were obtained from the U.S. Outpatient Influenza-like Illness Surveillance Network 290 (ILINet) and World Health Organization/National Respiratory and Enteric Virus Surveillance 291 System (WHO/NREVSS) Collaborating Labs (22). For the 1976-77 to the 1996-97 seasons, ILI 292 was assumed to be the mean ILI of the above seasons, and the numbers of respiratory specimens 293 were obtained from Thompson *et al.* 2003 (23). Each I_t from the 1976-77 season to the 2016-17 294 season was normalized by dividing by the mean of I_t across the seasons. For seasons from 1918-295 19 to 1975-76, we assumed that the intensity of influenza A to be 1.

We calculated the probability of having the first influenza A exposure to subtype H3N2 by taking the approach of Gostic *et al.* 2016 (4), assigning the probability of infection for naïve individuals a value of 0.28. Then the seasonal attack rate α was calculated by assuming exponential hazard as in Arevalo *et al.* 2019 (24):

300

$$\alpha = -\log(1 - 0.28)$$

First, we calculated the probability of having the first influenza A exposure in each season for individuals of the same age. We defined individuals of age *a* to be born in time *y*, from the beginning of July in year *y*-1 to the end of June in year *y*, where year *y* is 2017 - *a*. The probability of having the first influenza A exposure in season *t* for individuals born in time *y* is

$$p_{y,t}^{A} = \epsilon_{y,t}^{A} n_{y,t}^{A}$$

where $\epsilon_{y,t}^{A}$ is the probability of infection with influenza A for naïve individuals born in time *y* in season *t*, and $n_{y,t}^{A}$ is the probability of being naïve to influenza A at the beginning of season *t*. Specifically,

$$\epsilon_{y,t}^{A} = 1 - e^{-I_t F_{y,t} \alpha}$$

310
$$n_{y,t}^{A} = \begin{cases} 1, & t = y \\ n_{y,t-1}^{A}(1 - \epsilon_{y,t}^{A}), & t > y \end{cases}$$

Here, $F_{y,t}$, a fraction of a season *t* experienced by individuals born in time *y*, was introduced because individuals younger than 6 months of age are assumed not be exposed to influenza due to maternal immunity (see below).

Next, the probability that a cohort born in time *y* had its first influenza A exposure with subtype H3N2, P_y , is calculated as

316
$$P_{y} = \sum_{t=y}^{y+k} p_{y,t}^{A} q_{t}^{H3}$$

where q_t^{H3} is the frequency of H3N2 among influenza A cases in season *t*, and *k* is the maximum age of having a primary influenza A infection (effectively a numerical correction). Here, we set *k* to be 20 for individuals of 20 years or older, and to be the age for individuals younger than 20 years. The choice of *k* minimally affected the value of P_y .

321 Fraction of season experienced

We calculated the fraction of each season experienced by each cohort following the approach of Arevalo *et al.* 2019 (24). First, we calculated the fraction of a given influenza season during the week *w* of season *t*, $f_{w,t}$ as

325
$$f_{w,t} = \frac{\prod_{w,t} Q_{w,t}}{N_{w,t} \sum_{w'=w_0}^{w_f} \frac{\prod_{w',t} Q_{w',t}}{N_{w',t}}}$$

where $ILI_{w,t}$ is the weighted fraction of patients with ILI in week w of season t, $Q_{w,t}$ is the number 326 327 of respiratory specimens testing positive to influenza A in week w of season t, and $N_{w,t}$ is the 328 number of specimens tested in week w of season t. Parameters w_0 and w_f are the first and the 329 final week of season t. For seasons before 1997-98, weekly data were unavailable. Therefore, for 330 these seasons, we used the mean $f_{w,t}$ of a given week w from the 1997-98 to the 2017-18 331 seasons. We calculated the fraction of an influenza season experienced by an individual born in time y, $F_{y,t}$, using $f_{w,t}$ and the proportion of individuals born in time y that are over 6 months old 332 333 in week w of season t, $p_{v,w,t}$:

147 -

334
$$F_{y,t} = \sum_{w=w_0}^{w_f} f_{w,t} \, p_{y,w,t}$$

335 Amino acid similarity between the imprinting H3 virus and a test virus

To calculate the amino acid similarity between H3 viruses encountered early in life and a test virus, we calculated the probability of having the first influenza H3N2 exposure in season *t* for individuals born in time *y* as

339 $p_{v,t}^{\text{H3}} = \epsilon_{v,t}^{\text{H3}} n_{v,t}^{\text{H3}}$

where $\epsilon_{y,t}^{\text{H3}}$ is the probability of H3N2 infection for naïve individuals born in time *y* in season *t*, and $n_{y,t}^{\text{H3}}$ is the probability of being naïve at the start season *t*, i.e.,

342
$$\epsilon_{v,t}^{\text{H3}} = 1 - e^{-l_t f_{y,t} q_t^{\text{H3}} \alpha}$$

343
$$n_{y,t}^{\text{H3}} = \begin{cases} 1, & t = y \\ n_{y,t-1}^{\text{H3}}(1 - \epsilon_{y,t-1}^{\text{H3}}), & t > y \end{cases}$$

To calculate amino acid similarity, the H3 sequence samples were downloaded from Global Initiative on Sharing All Influenza Data in August 2018 (25). For each season, we resampled 100 samples if the number of available sequences within the season exceeded 100. The amino acid

similarity between H3N2 strains circulating in season *t* and a test virus *v*, $s_{t,v}$, was calculated as the fraction of shared amino acids in HA head epitopes (26).

349
$$s_{t,v} = \sum_{j=1}^{m_t} \sum_{r=1}^l \delta_{v,j,r} / lm_t$$

where m_t is the number of H3 sequence samples collected in season t, j is the index for the sample, l is the number of residues in the H3 head epitopes, r is the index for the residue, and $\delta_{j,r,v}$ is an indicator for the match of the amino acid between a test virus v and sample j at residue r. The value of $\delta_{j,r,v}$ is 1 if the amino acids match and 0 otherwise. For seasons before 1991-92, where the precise date of sequence isolation was unavailable, we obtained $s_{t,v}$ by calculating the average of s_v of year t-1 and year t, weighted by the average fraction of sequences from year t-1 and from year t for season t, calculated from seasons from 1991-92 to 2016-17.

Finally, the expected amino acid similarity between the first H3 virus encountered in life and a test virus *v* for individuals born in time *y* is

359
$$S_{y,v} = \sum_{t=y}^{y+k} p_{y,t}^{H3} s_{t,v}$$

360 We assumed that individuals born before 1967 to have the same amino acid similarity as 361 individuals born in 1967.

362 <u>Regression model</u>

To investigate associations between H3 imprinting, the amino acid similarity between the first H3 virus encountered in life and a test virus, and titers to the test virus, we performed a linear regression,

366
$$H_{iv} = \beta_1 P_{y_i} + \beta_2 S_{y_i,v} + \beta_3 V_{a_i} + c_v + c,$$

where $H_{i,v}$ is individual *i*'s log₂ FRNT titer to test virus *v*, P_{y_i} is the probability of imprinting to H3 for individual *i* born in birth time *y*, $S_{y_i,v}$ is the expected amino acid similarity between the first H3

medRxiv preprint doi: https://doi.org/10.1101/2020.01.09.20017038; this version posted January 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

virus encountered by the birth cohort to which individual *i* belongs and test virus *v*, V_{a_i} is the vaccination coverage for people the same age as individual *i*, c_v is a virus-specific intercept, and *c* is constant. Age-specific vaccine coverage from Pennsylvania state for the 2016-17 season was obtained from National Immunization Survey-Flu (NIS-Flu) and Behavioral Risk Factor Surveillance System (BRFSS) (26). We also evaluated models with a linear age effect as

374
$$H_{i,v} = \beta_1 P_{y_i} + \beta_2 S_{y_i,v} + \beta_3 V_{a_i} + \beta_4 a_i + c_v + c,$$

where β_4 is the coefficient for age. Finally, we evaluated whether there was support for titer differences in two epidemiologically distinct age groups, children (<18 years old) and adults (≥ 18 years old):

378
$$H_{i,v} = \beta_1 P_{y_i} + \beta_2 S_{y_i,v} + \beta_3 V_{a_i} + c_{g_i} + c_v + c$$

where c_{g_i} is the effect for age group *g* of individual *i*. We used the glm function in R (version 3.4.2) to fit linear models.

381 Statistical analysis

382 Data are presented as geometric mean antibody levels with 95% confidence intervals (CI) if not 383 stated otherwise. Analyses were performed using GraphPad Prism (version 7) or R (version 384 3.4.2). To compare titers between age groups, we performed bootstrap tests according to Hall 385 and Wilson 1991 (27). For a given pair of age groups, we calculate mean titer difference, $\hat{\theta}$, and 386 tested if it is significantly greater than zero. The bootstrap value of $\hat{\theta}$, $\hat{\theta}^*$, is obtained by resampling 387 individuals in each age group with replacement. We obtained the distribution of $\hat{\theta}^*$ from 20,000 resamplings. The distribution of $\hat{\theta}$ under a null hypothesis of $\hat{\theta} = 0$ is $\hat{\theta}^* - \hat{\theta}$ and we calculated p 388 389 values from this null distribution. Bootstrapping was performed for every pair of age groups. We 390 then used Bonferroni correction for multiple comparisons by dividing 0.05 by 72, the number of

- 391 all pairs of age groups. Therefore, a null hypothesis is rejected if p < 0.0007. Pre- and post-
- 392 infection titers during the 2014-2015 season were log₂-transformed and then compared using the
- 393 paired t- test. P values <0.05 were considered as statistically significant.

394

396 **References**

- 397 1. Bodewes R, de Mutsert G, van der Klis FRM, Ventresca M, Wilks S, Smith DJ, et al.
- 398 Prevalence of antibodies against seasonal influenza A and B viruses in children in
- 399 Netherlands. Clin Vaccine Immunol. 2011;18(3):469–76.
- 400 2. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, et al. Antibody
- 401 landscapes after influenza virus infection or vaccination. Science. 2014;346(6212):996–
 402 1000.
- 403 3. Francis T. On the doctrine of original antigenic sin. Proc Am Philos Soc.
- 404 1960;104(6):572–8.
- 405 4. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1

406 and H7N9 influenza via childhood hemagglutinin imprinting. Science.

- 407 2016;354(6313):722–6.
- 408 5. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and 409 evaluation. Hum Vaccin Immunother. 2018;14(8):1840–7.
- 410 6. Yokoyama M, Fujisaki S, Shirakura M, Watanabe S, Odagiri T, Ito K, et al. Molecular
- 411 dynamics simulation of the influenza A(H3N2) hemagglutinin trimer reveals the structural
- 412 basis for adaptive evolution of the recent epidemic clade 3C.2a. Front Microbiol.
- 413 2017;8:584.
- World Health Organization. Recommended composition of influenza virus vaccines foruse in the 2019-2020 northern hemisphere influenza season.
- 416 8. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, et al.
- 417 Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of
- 418 antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci. 2017 Nov
- 419 21;114(47):12578–83.
- 420 9. Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, et al. Update: Influenza

- 421 Activity in the United States During the 2017–18 Season and Composition of the 2018–
- 422 19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2018;67(22):634–42.
- 423 10. Neher RA, Bedford T. Nextflu: real-time tracking of seasonal influenza virus evolution in
 424 humans. Bioinformatics. 2015;31(21):3546–8.
- 425 11. Wohlbold T, Krammer F. In the shadow of hemagglutinin: A growing interest in influenza
- 426 viral neuraminidase and its role as a vaccine antigen. Viruses. 2014 Jun 23;6(6):2465–
- 427 94.
- 428 12. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, et al. An
- 429 optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase
- 430 inhibition antibody titers in human sera. J Virol Methods. 2014 Dec 15;210:7–14.
- 431 13. Wan H, Gao J, Yang H, Yang S, Harvey R, Chen Y-Q, et al. The neuraminidase of
- 432 A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong
 433 Kong/4801/2014 vaccine strain. Nat Microbiol. 2019 Aug 12;
- 434 14. Malosh R, Ohmit SE, Petrie JG, Thompson MG, Aiello AE, Monto AS. Factors associated
- 435 with influenza vaccine receipt in community dwelling adults and their children. Vaccine.
- 436 2014;32(16):1841–7.
- Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, et al. Influenza
 vaccine effectiveness in the United States during the 2016–2017 season. Clin Infect Dis.
 2019 May 17;68(11):1798–806.
- 440 16. Rolfes MA, Flannery B, Chung J, O'Halloran A, Garg S, Belongia EA, et al. Effects of
- influenza vaccination in the United States during the 2017–2018 influenza season. Clin
 Infect Dis. 2019;69(11):1845–53.
- 443 17. Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, et al. Interim
- 444 estimates of 2018–19 seasonal influenza vaccine effectiveness United States,
- 445 February 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135–9.
- 446 18. Levine MZ, Martin ET, Petrie JG, Lauring AS, Holiday C, Jefferson S, et al. Antibodies

- 447 against egg- and cell-grown influenza A(H3N2) viruses in adults hospitalized during the
 448 2017-2018 season. J Infect Dis. 2019;219(12):1904–12.
- 449 19. Lin Y, Wharton SA, Whittaker L, Dai M, Ermetal B, Lo J, et al. The characteristics and
- 450 antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza
- 451 A(H3N2) viruses passaged in MDCK cells. Influenza Other Respi Viruses.
- 452 2017;11(3):263–74.
- 453 20. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of
- 454 hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015
- 455 influenza season. Cell Rep. 2015;12(1):1–6.
- 456 21. Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng N-Y, Andrews S, et al. Preexisting
- 457 human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest.
- 458 2015;125(3):1255–68.
- 459 22. Centers for Disease Control and Prevention. FluView national, regional, and state level
- 460 outpatient illness and viral surveillance 2018 [Internet]. [cited 2019 Nov 6]. Available from:
- 461 https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html
- 462 23. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality
- 463 associated with influenza and respiratory syncytial virus in the United States. JAMA.
- 464 2003;289(2):179.
- 465 24. Arevalo P, Mclean HQ, Belongia EA, Cobey S. Earliest infections predict the age
- distribution of seasonal influenza A cases. medRxiv [Internet]. [cited 2019 Oct 30];
- 467 Available from: http://dx.doi.org/10.1101/19001875
- Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to
 reality. Euro Surveill. 2017;22(13):30494.
- 470 26. Shih AC-C, Hsiao T-C, Ho M-S, Li W-H. Simultaneous amino acid substitutions at
- 471 antigenic sites drive influenza A hemagglutinin evolution. Proc Natl Acad Sci U S A.
- 472 2007;104(15):6283–8.

- 473 27. Hall P, Wilson SR. Two guidelines for bootstrap hypothesis testing. Biometrics.
- 474 1991;47(2):757.
- 475
- 476

477 Acknowledgements

- 478 This work was supported by the National Institute of Allergy and Infectious Diseases
- 479 (1R01AI113047, S.E.H.; 1R01AI108686, S.E.H.; 1R01AI097150, A.S.M.; CEIRS
- 480 HHSN272201400005C, S.E.H., S.C., E.T.M., A.S.M. A.B., D.J.T.) and Center for Disease
- 481 Control (U01IP000474, A.S.M.). Scott E. Hensley holds an Investigators in the Pathogenesis of
- 482 Infectious Disease Awards from the Burroughs Wellcome Fund.
- 483

484 Author contributions

- 485 S.G., M.W., and M.G. completed experiments and analyzed data. K.K. and S.C. analyzed data
- 486 and completed modeling studies. A.B., D.J.T., E.T.M., and A.S.M. provided serum samples from
- 487 individuals before and after PCR-confirmed H3N2 infection. S.E.H. conceived the project and
- 488 supervised the work. S.G. and S.E.H. wrote the manuscript with input from all authors.

489

490 **Competing interests**

491 S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work

492 unrelated to this report. A.S.M. has received consultancy fees from Sanofi Pasteur, Seqirus,

- 493 and Novavax for work unrelated to this report. A.B. reports has received consultancy fees from
- 494 GSK and Merck and grant support from Merck, Pfizer, and Janssen for work unrelated to this
- 495 report. All other authors report no potential conflicts.



497

498 Figure 1. Antibody titers to contemporary A(H3N2) viruses in serum collected prior to the 2017-2018 499 season, ELISAs were completed to quantify the levels of 3c2.A (A) and 3c2.A2 (D) HA-specific IqG in 500 serum from different aged humans. FRNTs were completed to quantify the levels of 3c2.A (B) and 3c2.A2 501 (E) neutralizing antibodies in serum from different aged humans. ELLAs were completed with viruses that 502 had 3c2.A NA (C) and 3c2.A2 NA (F) to quantify NA-specific inhibitory antibodies in serum from different 503 aged humans. For A-F, the geometric mean titers are shown as cross bars and 95% confidence intervals 504 as error bars. (G-H) Data from panels A-F are summarized. Lines (blue=3c2.A; red=3c2.A2) are Loess 505 curves showing smoothed geometric mean titers with the 95% confidence intervals shaded. Dashed lines 506 in panels A-F represent the limit of detection for each assay.



508

Figure 2. Antibody responses in adults before and after laboratory-confirmed 3c2.A H3N2 infection during the 2014-2015 influenza season. Serum was collected from 14 adults before and after laboratory-confirmed 3c2.A H3N2 infection and we quantified (A) HA IgG binding antibodies by ELISA, (B) neutralizing antibodies by FRNTs, and (C) NA-specific antibodies by ELLAs. Dashed lines represent the limit of detection for each assay. Lines represent the geometric mean titers with 95% confidence intervals. Paired t tests were completed on log₂-transformed data, and p values are indicated.

515



517 518 519 Figure 3. Early life H3N2 imprinting affects antibodies against 3c2.A viruses. (A) H3 has evolved substantially since 1968 and residue differences between the HA of different H3N2 strains and the 3c2.A2 520 strain are indicated in red. Accession numbers EF409245 (1968), CY113261 (1977), U97740 (1989), 521 AJ311466 (1997) and EU199250 (2007) were aligned to accession number MH586372 (3c2.A2). (B) Top, 522 mean FRNT titers to 3c2.A (blue) and 3c2.A2 (red) viruses are shown by Loess curves (span=0.6) with the 523 95% CIs shaded. The probability that an individual was imprinted with H3N2 (i.e. their first influenza A virus 524 encounter was H3N2) is indicated with black line. Bottom, the antigenic similarity between the HA of an 525 individual's imprinting H3N2 strain and 3c2.A and 3c2.A2.

Age group (years)	Number of samples (n)
1-2	47
3-10	81
11-20	22
21-30	32
31-40	36
41-50	27
51-60	31
61-70	34*
71-90	42

527 **Extended Data Table 1.** Number of serum samples per age group.

⁵²⁸ * Sera from 2 participants in this age group were not tested in ELLA because of insufficient sample volume.

529 **Extended Data Table 2.** Comparisons of FRNT titers between age groups.

				30	:2.A				
	1-2	3-10	11-20	21-30	31-40	41-50	51-60	61-70	71-90
1-2		1.8587 (<0.0007)	0.5938 (0.0574)	0.7074 (0.0158)	0.0408 (0.459)	-0.487 (0.9449)	-0.2038 (0.7226)	0.2516 (0.2494)	0.5289 (0.0669)
3-10	-1.8587 (1)		-1.2649 (0.9998)	-1.1512 (0.9998)	-1.8179 (1)	-2.3457 (1)	-2.0625 (1)	-1.6071 (1)	-1.3298 (1)
11-20	-0.5938 (0.9426)	1.2649 (<0.0007)		0.1136 (0.384)	-0.553 (0.9488)	-1.0808 (0.9996)	-0.7977 (0.9846)	-0.3422 (0.8009)	-0.0649 (0.5689)
21-30	-0.7074 (0.9842)	1.1512 (<0.0007)	-0.1136 (0.616)		-0.6667 (0.9882)	-1.1944 (1)	-0.9113 (0.9973)	-0.4559 (0.8968)	-0.1786 (0.6922)
31-40	-0.0408 (0.541)	1.8179 (<0.0007)	0.553 (0.0512)	0.6667 (0.0122)		-0.5278 (0.9804)	-0.2446 (0.7802)	0.2108 (0.2574)	0.4881 (0.0627)
41-50	0.487 (0.0551)	2.3457 (<0.0007)	1.0808 (<0.0007)	1.1944 (<0.0007)	0.5278 (0.0202)		0.2832 (0.1703)	0.7386 (0.0154)	1.0159 (0.0009)
51-60	0.2038 (0.2774)	2.0625 (<0.0007)	0.7977 (0.0154)	0.9113 (0.0027)	0.2446 (0.2198)	-0.2832 (0.8298)		0.4554 (0.112)	0.7327 (0.019)
61-70	-0.2516 (0.7512)	1.6071 (<0.0007)	0.3422 (0.201)	0.4559 (0.1032)	-0.2108 (0.7426)	-0.7386 (0.9846)	-0.4554 (0.888)		0.2773 (0.2426)
71-90	-0.5289 (0.9332)	1.3298 (<0.0007)	0.0649 (0.4312)	0.1786 (0.3093)	-0.4881 (0.938)	-1.0159 (0.9991)	-0.7327 (0.981)	-0.2773 (0.7574)	
				3c	2.A2				
	1-2	3-10	11-20	21-30	31-40	41-50	51-60	61-70	71-90
1-2		1.8813 (<0.0007)	0.3936 (0.1677)	-0.1376 (0.654)	-0.6342 (0.9807)	-0.8471 (0.9966)	-0.558 (0.9424)	-0.5181 (0.939)	-0.3207 (0.8436)
3-10	-1.8813 (1)		-1.4877 (1)	-2.0189 (1)	-2.5154 (1)	-2.7284 (1)	-2.4393 (1)	-2.3994 (1)	-2.2019 (1)
11-20	-0.3936 (0.8327)	1.4877 (<0.0007)		-0.5312 (0.918)	-1.0278 (0.9986)	-1.2407 (0.9997)	-0.9516 (0.993)	-0.9118 (0.9924)	-0.7143 (0.9768)
21-30	0.1376 (0.348)	2.0189 (<0.0007)	0.5312 (0.083)		-0.4965 (0.9686)	-0.7095 (0.9968)	-0.4204 (0.9081)	-0.3805 (0.8962)	-0.183 (0.7386)
31-40	0.6342 (0.0193)	2.5154 (<0.0007)	1.0278 (0.0014)	0.4965 (0.0322)		-0.213 (0.8869)	0.0762 (0.3641)	0.116 (0.3028)	0.3135 (0.0778)
41-50	0.8471 (0.0034)	2.7284 (<0.0007)	1.2407 (<0.0007)	0.7095 (0.0032)	0.213 (0.1178)		0.2891 (0.1363)	0.329 (0.0859)	0.5265 (0.0075)
51-60	0.558 (0.0576)	2.4393 (<0.0007)	0.9516 (0.007)	0.4204 (0.0919)	-0.0762 (0.6358)	-0.2891 (0.8638)		0.0398 (0.4626)	0.2373 (0.2136)
61-70	0.5181 (0.0612)	2.3994 (<0.0007)	0.9118 (0.0076)	0.3805 (0.1046)	-0.116 (0.7005)	-0.329 (0.9142)	-0.0398 (0.5374)		0.1975 (0.2354)
71-90	0.3207 (0.1572)	2.2019 (<0.0007)	0.7143 (0.0238)	0.183 (0.2626)	-0.3135 (0.9248)	-0.5265 (0.9928)	-0.2373 (0.7864)	-0.1975 (0.7652)	

530

531 Each cell shows a titer difference (column minus row) between age groups (in years). P-values for the 532 differences were calculated using bootstrapping and are shown in parentheses. After applying Bonferroni 533 correction for multiple comparisons, p<0.0007 indicates the difference is significantly greater than 0.

534

Extended Data Table 3. The estimates of the effects of imprinting, vaccine coverage effect, and virus

538 specific effect.

Variable	Estimate (standard error)	р	AIC
Model 1			2647.5
Imprinting to H3	0.17 (0.30)	0.58	
Amino acid similarity between first virus in life and a test virus	H3 3.45 (0.38)	<0.001	
Vaccine coverage	3.86(0.56)	<0.001	
Virus effect for 3c2.A2	-0.23(0.12)	0.05	
Model 2 (with linear age effect)			2648.9
Imprinting to H3	0.33 (0.36)	0.37	
Amino acid similarity between first virus in life and a test virus	H3 3.57 (0.41)	<0.001	
Age	0.003 (0.003)	0.44	
Vaccine coverage	4.19 (0.71)	<0.001	
Virus effect for 3c2.A2	-0.23 (0.12)	0.06	
Model 3 (with age group effect for <18)			2649.4
Imprinting to H3	0.12 (0.32)	0.71	
Amino acid similarity between first virus in life and a test virus	H3 3.37 (0.44)	<0.001	
Age group <18	0.08 (0.24)	0.73	
Vaccine coverage	3.60 (0.94)	<0.001	
Virus effect for 3c2.A2	-0.23 (0.12)	0.05	



Extended Data Figure 1. Percentage of individuals with a \geq 4-difference in neutralizing antibody titers as

544 measured in FRNT in Figure 1.





Extended Data Figure 2. Antibody responses in adults before and after laboratory-confirmed 3c2.A H3N2 548 infection during the 2016-2017 influenza season. Serum was collected from 6 adults before and after 549 laboratory-confirmed 3c2.A H3N2 infection and we quantified (A) HA IgG binding antibodies by ELISA, (B) 550 neutralizing antibodies by FRNTs, and (C) NA-specific antibodies by ELLAs. Dashed lines represent the 551 limit of detection for each assay. Lines represent the geometric mean titers with 95% confidence intervals. 552 Paired t tests were completed on log₂-transformed data, and p values are indicated. 553

554 555